Tag Archives: systematic review

Review on acceptability and WTP for HIV vaccine

J. Pharm. Pharmacogn. Res., vol. 10, no. 4, pp. 748-767, July-August 2022.


Acceptability of and willingness to pay for human immunodeficiency virus vaccination: A systematic literature review

[Aceptabilidad y disposición a pagar por la vacunación contra el virus de la inmunodeficiencia humana: Una revisión sistemática de la literatura]

Tram N.T. Huyen1, Somying Pumtong1, Sermsiri Sangroongruangsri1, Luerat Anuratpanich1,2*

1Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.

2Department of Pharmacy, Division of Social and Administrative Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.

*E-mail: luerat.anu@mahidol.ac.th


Context: Vaccines for the human immunodeficiency virus (HIV) have considerably improved public health in the last century. Important considerations, however, are that effective vaccination substantially depends on the acceptability of future vaccines and that monetary measurements of vaccine preference, as reflected by the willingness to pay (WTP), may help policymakers establish health capital priorities.

Aims: To systematically pool data on vaccine acceptability and WTP.

Methods: A systematic search was performed over five databases to identify eligible articles published from 2005 to 2020, and key terms were used in accordance with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analyses. Two researchers independently assessed the articles, extracted relevant data, and drew numerical and descriptive summaries for result presentation via Excel.

Results: Out of 31 eligible studies, 28 and 3 reported on the acceptability of and WTP for HIV vaccination, respectively. Acceptability levels ranged from 2.94% to 93.10%, with the average being 60.16%, and WTP values fell between US$108 and US$671. The most prevalent themes were the characteristics of HIV vaccines (safety/side effects, efficacy, duration of protection, vaccine-induced seropositivity).

Conclusions: Overall, the review uncovered a lack of standardized, universal, and acceptable scales for determining acceptability and WTP. The evaluation provided a comprehensive and systematic summary of these matters along with useful information for policymakers on maximizing public health under limited resources.

Keywords: acceptability; HIV; immunization; systematic review; vaccination; willingness-to-pay.



Contexto: Las vacunas contra el virus de la inmunodeficiencia humana (VIH) han mejorado considerablemente la salud pública en el último siglo. Las consideraciones importantes, sin embargo, son que la vacunación efectiva depende sustancialmente de la aceptabilidad de las vacunas futuras y que las mediciones monetarias de la preferencia por la vacuna, reflejadas en la disposición a pagar (WTP), pueden ayudar a los formuladores de políticas a establecer prioridades de capital de salud.

Objetivos: Agrupar sistemáticamente los datos sobre la aceptabilidad de las vacunas y la disposición a pagar.

Métodos: Se realizó una búsqueda sistemática en cinco bases de datos para identificar artículos elegibles publicados entre 2005 y 2020, y se utilizaron términos clave de acuerdo con las pautas de Preferred Reporting Items for Systematic Review and Meta-Analyses. Dos investigadores evaluaron de forma independiente los artículos, extrajeron datos relevantes y elaboraron resúmenes numéricos y descriptivos para la presentación de resultados a través de Excel.

Resultados: De los 31 estudios elegibles, 28 y 3 informaron sobre la aceptabilidad y la disposición a pagar por la vacunación contra el VIH, respectivamente. Los niveles de aceptabilidad oscilaron entre 2,94 % y 93,10 %, con un promedio de 60,16 %, y los valores de disposición a pagar estuvieron entre US$ 108 y US$ 671. Los temas más predominantes fueron las características de las vacunas contra el VIH (seguridad/efectos secundarios, eficacia, duración de la protección, seropositividad inducida por la vacuna).

Conclusiones: En general, la revisión descubrió la falta de escalas estandarizadas, universales y aceptables para determinar la aceptabilidad y la disposición a pagar. La evaluación brindó un resumen completo y sistemático de estos asuntos junto con información útil para los formuladores de políticas sobre cómo maximizar la salud pública con recursos limitados.

Palabras Clave: aceptabilidad; inmunización; revisión sistemática; vacunación; VIH; voluntad de pago.


Citation Format: Huyen TNT, Pumtong S, Sanroongruangsri S, Anuratpanich L (2022) Acceptability of and willingness to pay for human immunodeficiency virus vaccination: A systematic literature review. J Pharm Pharmacogn Res 10(4): 748–767.

Atujuna M, Newman PA, Wallace M, Eluhu M, Rubincam C, Brown B, Bekker LG (2018) Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study. PLOS ONE 13: e0191251.

Bakari M, Munseri P, Francis J, Aris E, Moshiro C, Siyame D, Janabi M, Ngatoluwa M, Aboud S, Lyamuya E (2013) Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania-the phase I/II HIVIS 03 trial. BMC Public Health 13: 1149.

Barrington C, Moreno L, Kerrigan D (2007) Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care 19: 871-877.

Barrington C, Moreno L, Kerrigan D (2008) Perceived influence of an HIV vaccine on sexual‐risk behaviour in the Dominican Republic. Cult Health Sex 10: 391-401.

Boardman AE, Greenberg DH, Vining AR, Weimer DL (2017) Cost-benefit analysis: concepts and practice, 4th edn. Cambridge, UK: Cambridge University Press.

Cameron MP, Newman PA, Roungprakhon S, Scarpa R (2013) The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 31: 3712-3717.

Cook J, Jeuland M, Maskery B, Lauria D, Sur D, Clemens J, Whittington D (2009) Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. J Policy Anal Manage 28: 6-28.

Crosby RA, Holtgrave DR, Bryant L, Frew PM (2004) Correlates of negative intent to receive an AIDS vaccine: An exploratory study. Int J STD AIDS 15: 552-557.

Dhalla S, Poole G (2011) Motivators of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies. AIDS Care 23: 1430-1447.

Dimi S, Zucman D, Chassany O, Lalanne C, Prazuck T, Mortier E, Majerholc C, Aubin-Auger I, Verger P, Duracinsky M (2019) Patients’ high acceptability of a future therapeutic HIV vaccine in France: A French paradox? BMC Infect Dis 19: 401.

Doshi M, Avery L, Kaddu RP, Gichuhi M, Gakii G, Du Plessis E, Dutta S, Khan S, Kimani J, Lorway RR (2017) Contextualizing willingness to participate: Recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. BMC Public Health 17: 469.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford, UK: Oxford University Press.

Frew PM, Crosby RA, Salazar LF, Gallinot LP, Bryant LO, Holtgrave DR (2008) Acceptance of a potential HIV/AIDS vaccine among minority women. J Natl Med Assoc 100: 802-816.

Hom D, Johnson J, Mugyenyi P, Byaruhanga R, Kityo C, Louglin A, Svilar G, Vjecha M, Mugerwa R, Ellner J (1997) HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immune Defic Syndr 15: 375-380.

Kakinami L, Newman PA, Lee SJ, Duan N (2008) Differences in HIV vaccine acceptability between genders. AIDS Care 20: 542-546.

Keyserlingk CV, Rhodes B (2007) Using contingent valuation in hypothetical settings: Estimating the WTP for an HIV/AIDS vaccine. J Interdiscip Econ 18: 71-89.

Kim SY, Sagiraju H, Russell LB, Sinha A (2014) Willingness-to-pay for vaccines in low-and middle-income countries: A systematic review. Ann Vaccines Immunization 1: 1001.

Koniak D, Nyamathi A, Tallen L, González-Figueroa E, Dominick E (2007) Breaking the silence: What homeless 18-to 24-year-olds say about HIV vaccine trials. J Health Care Poor Underserved 18: 687-698.

Kontomanolis EN, Michalopoulos S, Gkasdaris G, Fasoulakis Z (2017) The social stigma of HIV-AIDS: Society’s role. HIV AIDS 9: 111-118.

Kpanake L, Gbandey S, Sorum PC, Mullet E (2018) Acceptability of vaccination against HIV: A mapping of Togolese people’s positions. J H Psychol 23: 800-806.

Lally M, Gaitanis M, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich J (2006) Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 43: 402-405.

Lee SJ, Brooks RA, Newman PA, Seiden D, Sangthong R, Duan N (2008) HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 20: 1161-1168.

Lee SJ, Newman PA, Duan N, Cunningham WE (2014) Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES. Vaccine 32: 5013-5018.

Lee S, Newman P, Comulada W, Cunningham W, Duan N (2012) Use of conjoint analysis to assess HIV vaccine acceptability: Feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS 23: 235-241.

Liau A, Zimet GD, Fortenberry JD (1998) Attitudes about human immunodeficiency virus immunization: The influence of health beliefs and vaccine characteristics. Sex Transm Dis 25: 76-81.

Lindegger G, Quayle M, Ndlovu M (2007) Local knowledge and experiences of vaccination: Implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav 34: 108-123.

Mays RM, Zimet GD (2004) Recommending STI vaccination to parents of adolescents: The attitudes of nurse practitioners. Sex Transm Dis 31: 428-432.

Newman P, Woodford M, Logie C (2012a) HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health 7: 87-100.

Newman PA, Duan N, Lee SJ, Rudy ET, Seiden DS, Kakinami L, Cunningham WE (2006) HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine 24: 2094-2101.

Newman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, Kakinami L, Shoptaw S, Diamant A, Cunningham WE (2009) Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high‐risk adults in Los Angeles (L.A. VOICES). Health Serv Res 44: 2167-2179.

Newman PA, Logie C (2010) HIV vaccine acceptability: a systematic review and meta-analysis. Aids 24: 1749-1756.

Newman PA, Roungprakhon S, Tepjan S, Yim S (2010) Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 28: 958-964.

Newman PA, Roungprakhon S, Tepjan S, Yim S, Walisser R (2012b) A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health 7: 1009-1024.

Nguyen F (2007) Gauging the acceptability of HIV vaccines: An exploratory study examining knowledge, attitudes, and beliefs among injecting drug users in Viet Nam. J Ethn Cult Divers Soc Work 16: 161-192.

Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R (2008) Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 20: 106-115.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews BMJ 372: n71.

Painter J, Cene-Kush C, Conner A, Cwiak C, Haddad L, Mulligan M, Diclemente R (2013) Anticipated HIV vaccine acceptability among sexually active African-American adult women. Vaccines 1: 88-104.

Ravert RD, Zimet GD (2009) College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav 33: 391-399.

Roberts KJ, Newman PA, Duan N, Rudy ET (2005) HIV vaccine knowledge and beliefs among communities at elevated risk: Conspiracies, questions and confusion. J Natl Med Assoc 97: 1662.

Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS (2005) HIV vaccine acceptability among women at risk: Perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev 17: 253-267.

Salazar LF, Holtgrave D, Crosby RA, Frew P, Peterson JL (2005) Issues related to gay and bisexual men’s acceptance of a future AIDS vaccine. Int J STD AIDS 16: 546-548.

Sayles JN, Macphail CL, Newman PA, Cunningham WE (2010) Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 37: 193-210.

Suraratdecha C, Hecht R (2005) Demand for a Preventive HIV Vaccine: A Review of the Literature. International AIDS Vaccine Initiative. Policy Research Working Paper # 3; pp. 39.

Thabethe S, Slack C, Lindegger G, Wilkinson A, Wassenaar D, Kerr P, Bekker LG, Mngadi K, Newman PA (2018) “Why don’t you go into suburbs? Why are you targeting us?”: Trust and mistrust in HIV vaccine trials in South Africa. J Empir Res Hum Res Ethics 13: 525-536.

Tremouillaux-Guiller J, Moustafa K, Hefferon K, Gaobotse G, Makhzoum A (2020) Plant-made HIV vaccines and potential candidates. Current Opinion in Biotechnology 61: 209-216.

Tsekoa TL, Singh AA, Buthelezi SG (2020) Molecular farming for therapies and vaccines in Africa. Curr Opin Biotechnol 61: 89-95.

Weaver J, Newman PA, Williams CC, Massaquoi N, Brown M (2013) “Sisters, Mothers, Daughters and Aunties”: HIV vaccine acceptability among African, Caribbean and other Black women in Toronto. Can J Public Health 104: e413-e417.

Whittington D, Suraratdecha C, Poulos C, Ainsworth M, Prabhu V, Tangcharoensathien V (2008) Household demand for preventive HIV/AIDS vaccines in Thailand: Do husbands’ and wives’ preferences differ? Value Health 11: 965-974.

Young AM, Diclemente RJ, Halgin DS, Sterk CE, Havens JR (2014) HIV vaccine acceptability among high-risk drug users in Appalachia: A cross-sectional study. BMC Public Health 14: 537.

Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM (2005) Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 37: 179-186.

© 2022 Journal of Pharmacy & Pharmacognosy Research (JPPRes)

Modified pectins with activity against colon cancer

J. Pharm. Pharmacogn. Res., vol. 10, no. 4, pp. 616-651, July-August 2022.


Pectinas modificadas con actividad contra el cáncer de colon: Una revisión sistemática de 2010-2021

[Modified pectins with activity against colon cancer: A systematic review from 2010-2021]

Matías Pérez-Loyola, Marisela Valdés-González, Gabino Garrido*

Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Angamos 0610, Antofagasta, Chile.

*E-mail: gabino.garrido@ucn.cl


Context: Colon cancer is a serious disease that can be hereditary or arise from exposure to carcinogens in unhealthy food. Current chemotherapy treatment has serious cardiovascular adverse effects, is not always effective, and there may be resistance to treatment. Recently, studies have found an optimal anticancer activity of modified pectins on colon cancer.

Aims: To systematically review the scientific literature, with PRISMA guidelines, of the articles found in the last 11 years, on the potential anticancer effects of pectins on colon cancer.

Methods: PRISMA and Rayyan were used for the selection of studies and a standardized search was followed in four databases with the terms: modified pectins, cancer, therapy. Data extraction was performed using Excel and relevant information on anticancer activity was collected.

Results: In total, 16 articles were included, finding seven in vitro, three mixed and six in vivo studies. The anticancer activity and optimization of the formulation, encapsulation, release of pectin-based drugs were evaluated by different methods in 12 and six articles, respectively. Most of the studies were classified as high quality with the AXIS tool. Furthermore, 11 out of 12 articles showed positive effects of modified pectins on colon cancer both in vivo and in vitro and six out of six articles found positive effects on pectin-based formulations.

Conclusions: The evidence found suggests a beneficial effect of modified pectins on colon cancer, however, more in vivo studies are required.

Keywords: colon cancer; modified pectin; systematic review; therapy.

This image has an empty alt attribute; its file name is jppres_pdf_free.png


Contexto: El cáncer de colon es una patología grave que puede ser hereditaria o surgir por exposición a carcinógenos en la alimentación no saludable. El tratamiento mediante quimioterapia actual posee efectos adversos cardiovasculares graves, no siempre es efectivo y puede existir resistencia al tratamiento. Recientemente, estudios han encontrado una óptima actividad anticancerígena de las pectinas modificadas sobre cáncer de colon.

Objetivos: Revisar sistemáticamente la literatura científica, con directrices PRISMA, de los artículos encontrados en los últimos 11 años, sobre los potenciales efectos anticancerígenos de las pectinas sobre el cáncer de colon.

Métodos: Se utilizó PRISMA y Rayyan para la selección de estudios y se siguió una búsqueda estandarizada en cuatro bases de datos con los términos: modified pectins, cancer, therapy. La extracción de datos se realizó mediante Excel y se recopilo información relevante sobre la actividad anticancerígena.

Resultados: En total, se incluyeron 16 artículos, encontrándose siete estudios in vitro, tres mixtos y seis in vivo. Se evaluó por diferentes métodos la actividad anticancerígena y la optimización de la formulación, encapsulación, liberación de fármacos a base de pectina, en 12 y seis artículos, respectivamente. Mayoritariamente, los estudios fueron clasificados de alta calidad con la herramienta AXIS. Además, 11 de 12 artículos mostraron efectos positivos de las pectinas modificadas sobre el cáncer de colon tanto in vivo como in vitro y seis de seis artículos obtuvieron efectos positivos en las formulaciones a base de pectina.

Conclusiones: La evidencia encontrada sugiere un efecto beneficioso de las pectinas modificadas sobre el cáncer de colon, sin embargo, se requieren más estudios in vivo.

Palabras Clave: cáncer de colon; pectina modificada; revisión sistemática; terapia.

This image has an empty alt attribute; its file name is jppres_pdf_free.png

Citation Format: Pérez-Loyola M, Valdés-González M, Garrido G (2022) Pectinas modificadas con actividad contra el cáncer de colon: Una revisión sistemática de 2010-2021. [Modified pectins with activity against colon cancer: A systematic review from 2010-2021]. J Pharm Pharmacogn Res 10(4): 616–651.

Aldulaymi R, Al Meslamani AZ (2022) Systematic review of the safety and efficacy of antazoline in the treatment of atrial fibrillation. J Pharm Pharmacogn Res 10(1): 147–157.

Almeida EAMS, Facchi SP, Martins AF, Nocchi S, Schuquel ITA, Nakamura CV, Rubira AF, Muniz EC (2015) Synthesis and characterization of pectin derivative with antitumor property against Caco-2 colon cancer cells. Carbohydr Polym 115: 139–145.

American Cancer Society [Internet]. Tratamiento. 2018. Disponible en: https://www.cancer.org/es/cancer/cancer-de-colon-o-recto/tratamiento.html [Consultado 7 noviembre 2021].

Arya M, Singh P, Tripathi CB, Parashar P, Singh M, Kanoujia J, Guleria A, Kaithwas G, Gupta KP, Saraf SA (2019) Pectin-encrusted gold nanocomposites containing phytic acid and jacalin: 1,2-dimethylhydrazine-induced colon carcinogenesis in Wistar rats, PI3K/Akt, COX-2, and serum metabolomics as potential targets. Drug Deliv Transl Res 9(1): 53–65.

Basak S, Annapure US (2022) Trends in “green” and novel methods of pectin modification – A review. Carbohydr Polym 278: 118967.

BeMiller JN (1967) Acid-catalyzed hydrolysis of glycosides. Adv Carbohydr Chem 22: 25–108.

Biagi G, Cipollini I, Grandi M, Zaghini G (2010) Influence of some potential prebiotics and fibre-rich foodstuffs on composition and activity of canine intestinal microbiota. Animal Feed Sci Technol 159(1): 50–58.

Blachier F, Beaumont M, Andriamihaja M, Davila AM, Lan A, Grauso M, Armand L, Benamouzig R, Tomé D (2017) Changes in the luminal environment of the colonic epithelial cells and physiopathological consequences. Am J Pathol 187(3): 476–486.

Cao J, Yang J, Wang Z, Lu M, Yue K (2020) Modified citrus pectins by UV/H2O2 oxidation at acidic and basic conditions: Structures and in vitro anti-inflammatory, anti-proliferative activities. Carbohydr Polym 247: 116742.

Cervantes A (2018) Resistencia a la quimioterapia: mecanismos y vías de modulación. Investigación sobre el cáncer en España: de la Biología Molecular a la clínica, pp. 93–99.

Chang C, Wang ZC, Quan CY, Cheng H, Cheng SX, Zhang XZ, Zhuo RX (2007) Fabrication of a novel pH-sensitive glutaraldehyde cross-linked pectin nanogel for drug delivery. J Biomater Sci Polym Ed 18(12): 1591–1599.

Chang WC, Chapkin RS, Lupton JR (1997) Predictive value of proliferation, differentiation and apoptosis as intermediate markers for colon tumorigenesis. Carcinogenesis 18(4): 721–730.

Charles River (2021) Modelos de Investigación y Servicios. Charles River Acquires Vigene Biosciences. Disponible en: https://www.criver.com/es [Consultado 18 de diciembre del 2021].

Chasquibol-Silva N, Arroyo-Benites E, Morales-Gomero J (2008) Extracción y caracterización de pectinas obtenidas a partir de frutos de la biodiversidad peruana. Ing Ind 26: 175–199.

Cheewatanakornkool K, Niratisai S, Manchun S, Dass CR, Sriamornsak P (2017) Characterization and in vitro release studies of oral microbeads containing thiolated pectin–doxorubicin conjugates for colorectal cancer treatment. Asian J Pharm Sci 12(6): 509–520.

Chen L, Hao M, Yan J, Sun L, Tai G, Cheng H, Zhou Y (2021) Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation. J Biol Chem 296: 100515.

Cheng H, Li S, Fan Y, Gao X, Hao M, Wang J, Zhang X, Tai G, Zhou Y (2011) Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells. Med Oncol 28(1): 175–181.

Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ, Lupton JR (2012) A chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat azoxymethane-induced carcinomas. Exp Biol Med 237(12): 1387–1393.

Clapper ML, Chang WL, Cooper HS (2020) Dysplastic aberrant crypt foci: biomarkers of early colorectal neoplasia and response to preventive intervention. Cancer Prev Res 13(3): 229–240.

Comoglu T, Savaşer A, Ozkan Y, Gönül N, Baykara T (2007) Enhancement of ketoprofen bioavailability by formation of microsponge tablets. Pharmazie 62(1): 51–54.

Courts FL (2013) Profiling of modified citrus pectin oligosaccharide transport across Caco-2 cell monolayers. PharmaNutrition 1(1): 22–31.

Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklöf V, Rutegård J, Oberg A, Van Guelpen BR (2010) The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 16(6): 1845–1855.

Das S, Ng KY, Ho PC (2011) Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: In vitro and in vivo evaluations. J Drug Target 19(6): 446–457.

Das S, Ng KY, Ho PC (2010) Formulation and optimization of zinc pectinate beads for the controlled delivery of resveratrol. AAPS PharmSciTech 11(2): 729–742.

do Prado SBR, Shiga TM, Harazono Y, Hogan VA, Raz A, Carpita NC, Fabi JP (2019) Migration and proliferation of cancer cells in culture are differentially affected by molecular size of modified citrus pectin. Carbohydr Polym 211: 141–151.

Downes MJ, Brennan ML, Williams HC, Dean RS (2016) Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open 6: e011458.

Eliaz I, Raz A (2019) Pleiotropic effects of modified citrus pectin. Nutrients 11(11): 2619.

Escobar L, Rivera A, Aristizabal FA (2010) Comparison of resazurin and MTT methods on studies of citotoxicity in human tumor cell lines. Vitae 17(1): 67–74.

Escobar ML (2007) Estudio comparativo de los métodos de rezasurina y MTT empleados en la evaluación de citotoxicidad sobre tres líneas celulares tumorales [tesis de pregrado]. Pontificia Universidad Javeriana, Bogotá, Colombia.

Escobar ML, Aristizabal FA, Alfonso P (2009) Valoración de dos métodos de tinción en ensayos de citotoxicidad sobre líneas celulares tumorales. Rev Col de Biotecnol 11(2): 49–56.

Fan L, Zuo S, Tan H, Hu J, Cheng J, Wu Q, Nie SP (2020) Preventive effects of pectin with various degrees of esterification on ulcerative colitis in mice. Food Funct 11: 2886–2897.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. (2020) Global Cancer Observatory: Cancer Today. Lyon: Centro Internacional de Investigaciones sobre el cáncer. Disponible en: https://gco.iarc.fr/today [Consultado el 09 de junio del 2021].

Ferreira-Lazarte A, Fernández J, Gallego-Lobillo P, Villar CJ, Lombó F, Moreno FJ, Villamiel M (2021) Behaviour of citrus pectin and modified citrus pectin in an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced rat colorectal carcinogenesis model. Int J Biol Macromol 167: 1349–1360.

Fröhlich E (2012) The role of surface charge in cell uptake and cytotoxicity of medical nanoparticles. Int J Nanomed 7: 5577–5591.

Gao X, Zhi Y, Sun L, Peng X, Zhang T, Xue H, Tai G, Zhou Y (2013) The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng Pectin on galectin-3 and its structure-activity relationship. J Biol Chem 288(47): 33953–33965.

Glinsky VV, Raz A (2009) Anti-metastatic properties of modified citrus pectin: one bullet, multiple targets. Carbohydr Res 344(14): 1788–1791.

Global Cancer Observatory (2020) New Global Cancer Data: GLOBOCAN 2020, UICC.

Grau de Castro JJ (2005) Inhibidores de la ciclooxigenasa-2 en la prevención del cáncer. Rev Clin Esp 205(9): 446–456.

Habermann N, Schön A, Lund EK, Glei M (2010) Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. Apoptosis 15(5): 621–630.

Hansen LT, Allan-Wojtas PM, Jin YL, Paulson AT (2002) Survival of Ca-alginate microencapsulated Bifidobacterium spp. in milk and simulated gastrointestinal conditions. Food Microbiol 19(1): 35–45.

Holze C, Michaudel C, Mackowiak C, Haas DA, Benda C, Hubel P (2018) Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway. Nat Immunol 19(2): 130–140.

Hu YL, Wang XB, Chen DD, Guo XJ, Yang QJ, Dong LH, Cheng L (2016) Germanicol induces selective growth inhibitory effects in human colon HCT-116 and HT29 cancer cells through induction of apoptosis, cell cycle arrest and inhibition of cell migration. J BUON 21(3): 626–632.

Inohara H, Raz A (1994) Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11(6): 527–532.

Instituto Nacional del Cáncer (2021) ¿Que es el cáncer?», NIH, Estados Unidos. Disponible en: https://www.cancer.gov/espanol/cancer/naturaleza/que-es [Consultado el 9 de junio del 2021].

Itriago GL, Silva NI, Cortes GF (2013) Cáncer en Chile y el mundo: Una mirada epidemiológica, presente y futuro. Rev Méd Clín Las Condes 24(4): 531–552.

Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, Gao MY, Shirley RB, Stoffel MT, Kumar MV, Mohnen D (2007) Pectin induces apoptosis in human prostate cancer cells: Correlation of apoptotic function with pectin structure. Glycobiology 17(8): 805–819.

Jacobasch G, Dongowski G, Florian S, Müller-Schmehl K, Raab B, Schmiedl D (2008) Pectin does not inhibit intestinal carcinogenesis in APC-deficient min/+ mice. J Agric Food Chem 56(4): 1501–1510.

Jacobs LR, Lupton JR (1986) Relationship between colonic luminal pH, cell proliferation, and colon carcinogenesis in 1,2-dimethylhydrazine treated rats fed high fiber diets. Cancer Res 46: 1727–1734.

Jar AM (2014) Bienestar animal y el uso de animales de laboratorio en la experimentación científica. Animal welfare and the use of laboratory animals in scientific research. Rev Argent Microbiol 46(2): 77–79.

Khazir J, Mir BA, Pilcher L, Riley DL (2013) Role of plants in anticancer drug discovery. Phytochem Lett 7(1): 173–181.

Kim WY, Kim JM, Han SB, Lee SK, Kim ND, Park MK, Kim CK, Park JH (2000) Steaming of ginseng at high temperature enhances biological activity. J Nat Prod 63(2):1702–1704.

Leclere L, Fransolet M, Cambier P, Bkassiny SEL, Tikad A, Dieu M, Vincent SP, Van Cutsem P, Michiels C (2016) Identification of a cytotoxic molecule in heat-modified citrus pectin. Carbohydr Polym 137: 39–51.

Leclere L, Van Cutsem P, Michiels C (2013) Anti-cancer activities of pH-or heat-modified pectin. Front Pharmacol 4: 128.

Li D-Q, Li J, Dong H-L, Li X, Zhang J-Q, Ramaswamy S, Xu F (2021) Pectin in biomedical and drug delivery applications: A review. Int J Biol Macromol 185: 49–65.

Li Y, Fan L, Niu Y, Mian W, Zhang F, Xie M, Mei Q (2017) An apple oligogalactan enhances the growth inhibitory effect of 5-fluorouracil on colorectal cancer. Eur J Pharmacol 804: 13–20.

Li Y, Niu Y, Sun Y, Mei L, Zhang B, Li Q, Liu L, Zhang R, Chen J, Mei Q (2014) An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer. Nutr Cancer 66(1): 29–37.

Liu L, Fishman ML, Kost J, Hicks KB (2003) Sistemas basados en pectina para la administración de fármacos específicos al colon por vía oral. Biomateriales 24(19): 3333–3343.

Liu L, Li YH, Niu YB, Sun Y, Guo ZJ, Li Q, Li C, Feng J, Cao SS, Mei QB (2010) An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-κB pathway in a mouse model of colitis-associated colon cancer. Carcinogenesis 31(10): 1822–1832.

Lizano Soberon M, Barrera Rodriquez R (1993) Resistencia múltiple a drogas: un problema en la quimioterapia de cáncer. Rev Invest Clin 45(5): 481–492.

López I, Balderas-Renteríac I, Gómeza I, González-Santiagoc O, González-Barrancoa P, Garza-Ocañas L, Ramírez-Cabrera MA (2020) MTT Vs WST-1, efficiency, cost, time, and waste generation: evaluating the silver nanoparticles cytotoxicity. Rev Cienc Farm Biomed 3: 3–12.

Marangoni VS, Paino IM, Zucolotto V (2013) Synthesis and characterization of jacalin-gold nanoparticles conjugates as specific markers for cancer cells. Colloids Surf B Biointerfaces 112: 380–386.

Martins AF, de Oliveira DM, Pereira AGB, Rubira AF, Muniz EC (2012) Chitosan/TPP microparticles obtained by microemulsion method applied in controlled release of heparin. Int J Biol Macromol 51(5): 1127–1133.

Mat Sharil AT, Ezzat MB, Widya L, Nurhakim Amri HM, Nor Hikmah AR, Nabilah Zafira Z, Haris MS (2022) Systematic review of flaxseed (Linum usitatissimum L.) extract and formulation in wound healing. J Pharm Pharmacogn Res 10(1): 1–12.

Maxwell EG, Belshaw NJ, Waldron KW, Morris VJ (2012) Pectin – an emerging bioactive food polysaccharide. Trends Food Sci Technol 24: 64–73.

Moghaddam FA, Atyabi F, Dinarvand R (2009) Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomed Nanotechnol Biol Med 5: 208–215.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339: b2535.

Morales Yera R, Sierra Pérez L, Triana Díaz A (2018) Cardiotoxicidad inducida por quimioterapia. CorSalud 10(1): 68–77.

Morris ER, Powell DA, Gidley MJ, Rees DA (1982) Conformations and interactions of pectins. I. Polymorphism between gel and solid states of calcium polygalacturonate. J Mol Biol 155(4): 507–516.

Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94(24): 1854–1862.

Odun-Ayo F, Mellem J, Naicker T, Reddy L (2015) Chemoprevention of azoxymethane-induced colonic carcinogenesis in Balb/c mice using a modified pectin alginate probiotic. Anticancer Res 35(9): 4765–4776.

Odun-Ayo F, Mellem J, Reddy L (2016) Improving the survival of probiotic in simulated conditions and azoxymethane induced colon tumor bearing mice using modified citrus pectin-alginate microencapsulation. Universidad Tecnológica, Cape Town, South. Afr J Tradit Complement Altern Med 13(2): 101–109.

Organización Mundial de la Salud (2021) Cáncer, WHO. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer [Consultado 3 de marzo 2021].

Orlandi P, Gentile D, Banchi M, Cucchiara F, Di Desidero T, Cremolini C, Moretto R, Falcone A, Bocci G (2020) Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. Investig New Drugs 38(1): 92–98.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1): 210.

Öztürk K, Mashal AR, Yegin BA, Çalış S (2017) Preparation and in vitro evaluation of 5-fluorouracil-loaded PCL nanoparticles for colon cancer treatment. Pharm Dev Technol 22(5): 635–641.

Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E2, transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8(3): 289–293.

Perše M, Anton C (2011) Morphological and molecular alterations of 1,2-dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol 2011: 473964.

Popov SV, Ovodov YS (2013) Polypotency of the immunomodulatory effect of pectins. Biochemistry 78(7): 823–835.

RevMan (2020) Review Manager [Computer program]. Version 5.4. The Cochrane Collaboration.

Rojas Castillo N, Zuñiga Corvalan C (2020) Potenciales Efectos Anticaries de Fibras Prebióticas: Una Revisión Sistemática de la Literatura [Tesis de Pregrado]. Universidad de Talca, Talca, Chile.

Romero-Fernandez W, Batista-Castro Z, De Lucca M, Ruano A, García-Barceló M, Rivera-Cervantes M, García-Rodríguez J, Sánchez-Mateo S (2016) El 1, 2, 3 de la experimentación con animales de laboratorio. Rev Perú Med Exp Salud Publica 33(2): 288–299.

Sabra R, Billa N, Roberts CJ (2018) An augmented delivery of the anticancer agent, curcumin, to the colon. React Funct Polym 123: 54–60.

Sabra R, Billa N, Roberts CJ (2019) Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. Int J Pharm 572: 118775.

Salama L, Pastor ER, Stone T, Mousa SA (2020) Emerging nanopharmaceuticals and nanonutraceuticals in cancer management. Biomedicines 8(9): 347.

Sánchez C (2013) Conociendo y comprendiendo la célula cancerosa: Fisiopatología Del Cáncer. Rev Méd Clín Las Condes 24(4): 553–562.

Santana-Gálvez J, Villela-Castrejón J, Serna-Saldívar SO, Cisneros-Zevallos L, Jacobo-Velázquez DA (2020) Synergistic combinations of curcumin, sulforaphane, and dihydrocaffeic acid against human colon cancer cells. Int J Mol Sci 21(9): 3108.

Saz-Peiró P, Tejero-Lainez MC (2016) Fitoterapia en la prevención y tratamiento del cáncer. Med Natur 10(2): 88–99.

Sriamornsak P, Nunthanid J (1998) Calcium pectinate gel beads for controlled release drug delivery: I. Preparation and in vitro release studies. Int J Pharm 160: 207–212.

Srivastava R, Kumar D, Pathak K (2012) Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. Int J Pharm 427(2):153–162.

Tremaroli V, Bäckhed F (2012) Interacciones funcionales entre la microbiota intestinal y el metabolismo del huésped. Nature 489 (7415): 242–249.

Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R (2002) Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 8(11): 3512–3519.

Valdespino-Gómez VM, Valdespino-Castillo PM, Valdespino-Castillo VE (2015) Interacción de las vías de señalización intracelulares participantes en la proliferación celular: potencial blanco de intervencionismo terapéutico. Cir Cir 83(2): 165–174.

Wang H, Gao Z, Liu X, Agarwal P, Zhao S, Conroy DW, Ji G, Yu J, Jaroniec CP, Liu Z, Lu X, Li X, He X (2018) Targeted production of reactive oxygen species in mitochondria to overcome resistance to anticancer drugs. Nat Commun 9(1): 562.

Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A (2010) Activation of calpain through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 1(11): 101–110.

Weber K (2017) Differences in types and incidence of neoplasms in Wistar Han and Sprague-Dawley rats. Toxicol Pathol 45(1): 64–75.

Wirtz S, Neufert C, Weigmann B, Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protocol 2(3): 541–546.

Wu KL, Kuo CM, Huang EY, Pan HM, Huang CC, Chen YF, Hsiao CC, Yang KD (2018) Extracellular galectin-3 facilitates the migration of colon cancer cells and is related to the epidermal growth factor receptor. Am J Transl Res 10(8): 2402–2412.

Zhang W, Xu P, Zhang H (2015) Pectin in cancer therapy: A review. Trends Food Sci Technol 44(2): 258–271.

Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X (2017a) Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8 (3): 3980–4000.

Zhao X, Pan J, Li W, Yang W, Qin L, Pan Y (2018) Gold nanoparticles enhance cisplatin delivery and potentiate chemotherapy by decompressing colorectal cancer vessels. Int J Nanomedicine 13: 6207–6221.

Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, Zhang S, Huang Q, Shi M (2017b) ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer 16(1): 79.

© 2022 Journal of Pharmacy & Pharmacognosy Research (JPPRes)

Wound healing ability of flaxseed extracts

J Pharm Pharmacogn Res 10(1): 1-12, 2022.


Systematic review of flaxseed (Linum usitatissimum L.) extract and formulation in wound healing

[Revisión sistemática sobre extracto y formulación de linaza (Linum usitatissimum L.) en la cicatrización de heridas]

Abdul Talib Mat Sharil1, Mustafa Basma Ezzat2, Lestari Widya2, Mat Husin Amri Nurhakim1, Ab Razak Nor Hikmah2, Zainon Nabilah Zafira2, Muhammad Salahuddin Haris1*

1Department of Pharmaceutical Technology, Kulliyyah of Pharmacy, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang, Malaysia.

2Department of Fundamental Dental and Medical Sciences, Kulliyyah of Dentistry, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, 25200, Kuantan, Pahang, Malaysia.

*E-mail: solah@iium.edu.my


Context: Flaxseed constituents provide to antioxidant, anti-inflammatory, antimicrobial and wound healing benefits.

Aims: To systematically review the experimental evidence on the wound healing ability of flaxseed extracts and formulations.

Methods: Comprehensive searches in six databases (Scopus, Science Direct, Web of Science, PubMed, Google Scholar and Dimensions) were carried out from the beginning of databases until December 2020, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. The terms used in searches were (Linum usitatissimum L., flaxseed, linseed, flax) AND (extract) AND (wound heal, heal, heal type, wound) for collection of articles, with only articles in English and research articles were included. Transgenic term were excluded. AXIS tool was chosen to assess the quality and risk of bias. The data were then categorised in term of extracts, laboratory formulation, and wound healing.

Results: In total, 999 articles were collected and screened based on the pre-determined inclusion and exclusion criteria. Finally, 10 articles were included in the review. The majority of publications reported significant findings of flaxseed oil on wound healing regardless of extraction method and formulation. Healing parameters on excision, incision, and burn wound models were studied. Lack of laboratory formulation mentioned in the collected articles gave limitation impact on this study.

Conclusions: Flaxseed oil formulation appears to exert a positive effect on wound healing. Therefore, extensive studies needed to evaluate the transportation of flaxseed phytochemicals into skin dermis by advanced drug formulation.

Keywords: extraction; flaxseed; formulation; Linum usitatissimum L.; systematic review; wound healing.

This image has an empty alt attribute; its file name is jppres_pdf_free.png

Contexto: Los componentes de la linaza proporcionan beneficios antioxidantes, antiinflamatorios, antimicrobianos y de cicatrización de heridas.

Objetivos: Revisar sistemáticamente las evidencias experimentales sobre la capacidad de cicatrización de heridas de los extractos y formulaciones de linaza.

Métodos: Se realizaron búsquedas integrales en seis bases de datos (Scopus, Science Direct, Web of Science, PubMed, Google Scholar y Dimensions) desde el inicio de las bases de datos hasta diciembre de 2020, según Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) protocolo. Los términos utilizados en las búsquedas fueron (Linum usitatissimum L., flaxseed, linseed, flax) AND (extracto) AND (herida curar, curar, curar tipo, herida) para la colección de artículos, con solo artículos en inglés y se incluyeron artículos de investigación. Se excluyeron los términos transgénicos. Se eligió la herramienta AXIS para evaluar la calidad y el riesgo de sesgo. Luego, los datos se clasificaron en términos de extractos, formulación de laboratorio y cicatrización de heridas.

Resultados: En total, se recopilaron y seleccionaron 999 artículos según los criterios de inclusión y exclusión predeterminados. Finalmente, se incluyeron 10 artículos en la revisión. La mayoría de las publicaciones informaron hallazgos significativos del aceite de linaza en la cicatrización de heridas, independientemente del método de extracción y la formulación. Se estudiaron los parámetros de curación en modelos de escisión, incisión y quemaduras. La falta de formulación de laboratorio mencionada en los artículos recopilados dio un impacto de limitación en este estudio.

Conclusiones: La formulación de aceite de linaza parece ejercer un efecto positivo en la cicatrización de heridas. Por lo tanto, se necesitaban estudios extensos para evaluar el transporte de fitoquímicos de la linaza a la dermis de la piel mediante una formulación avanzada de fármacos.

Palabras Clave: extracción; cicatrización de herida; formulación; Linum usitatissimum; revisión sistemática; semilla de lino.

This image has an empty alt attribute; its file name is jppres_pdf_free.png
Citation Format: Mat Sharil AT, Basma Ezzat M, Widya L, Amri Nurhakim MH, Nor Hikmah AR, Nabilah Zafira Z, Haris MS (2022) Systematic review of flaxseed (Linum usitatissimum L.) extract and formulation in wound healing. J Pharm Pharmacogn Res 10(1): 1–12.

© 2022 Journal of Pharmacy & Pharmacognosy Research (JPPRes)